Exploring Treatment Innovations in Metastatic Bladder Cancer

This chapter explores the potential of circulating tumor DNA in personalizing cancer therapy, highlighting updates from the ASCO 2025 regarding the EV302 trial. It emphasizes key aspects such as patient response rates, treatment toxicity management, and strategies for improving quality of life through treatment deescalation.